SG11201810199WA - ANTI-IgE ANTIBODIES - Google Patents
ANTI-IgE ANTIBODIESInfo
- Publication number
- SG11201810199WA SG11201810199WA SG11201810199WA SG11201810199WA SG11201810199WA SG 11201810199W A SG11201810199W A SG 11201810199WA SG 11201810199W A SG11201810199W A SG 11201810199WA SG 11201810199W A SG11201810199W A SG 11201810199WA SG 11201810199W A SG11201810199W A SG 11201810199WA
- Authority
- SG
- Singapore
- Prior art keywords
- ige
- ucb
- asthma
- international
- ipd
- Prior art date
Links
- 208000006673 asthma Diseases 0.000 abstract 6
- 239000000427 antigen Substances 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 239000011230 binding agent Substances 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 230000007246 mechanism Effects 0.000 abstract 3
- 230000000172 allergic effect Effects 0.000 abstract 2
- 208000010668 atopic eczema Diseases 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 230000003993 interaction Effects 0.000 abstract 2
- 101100042788 Caenorhabditis elegans him-1 gene Proteins 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229960000470 omalizumab Drugs 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 229940099073 xolair Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
- C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Endocrinology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization MD HIM 01E111 Minn 01111111 HIM 1 1111 EH ill 1111111 International Bureau (43) International Publication Date . . .., . .. WO 2017/211928 Al (10) International Publication Number 14 December 2017 (14.12.2017) WIP0 I PCT (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07K 16/28 (2006.01) C07K 16/42 (2006.01) C07K 14/735 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, (21) International Application Number: PCT/EP2017/063916 CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, (22) International Filing Date: 08 June 2017 (08.06.2017) KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (25) Filing Language: English SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (26) Publication Language: English TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 1610198.2 10 June 2016 (10.06.2016) GB 1702435.7 15 February 2017 (15.02.2017) GB kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (71) Applicant: UCB BIOPHARMA SPRL [BE/BE]; 60, Al- lee de la Recherche, 1070 Brussels (BE). TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (72) Inventors: ADAMS, Ralph; c/o IPD, UCB Celltech, 208 Bath Road, Slough Berkshire SL1 3WE (GB). CESKA, Thomas Allen; c/o IPD, UCB Celltech, 208 Bath Road, Slough Berkshire SL1 3WE (GB). DAVIES, Anna Marie; MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). King's College London, Randall Division of Cell & Mol- Declarations under Rule 4.17: ecular Biophysics, MRC & Asthma UK Centre in Aller- — as to applicant's entitlement to apply for and be granted a gic Mechanisms of Asthma, New Hunt's House, Guy's Hos- patent (Rule 4.17(ii)) pital Campus London SE1 1UL (GB). HENRY, Alistair — of inventorship (Rule 4.17(iv)) James; c/o IPD, UCB Celltech, 208 Bath Road, Slough Published: Berkshire SL1 3WE (GB). LIU, Xiaofeng; c/o IPD, UCB Celltech, 208 Bath Road, Slough Berkshire SL1 3WE (GB). — with international search report (Art. 21 (3)) — before the expiration of the time limit for amending the MCDONNELL, James Michael; King's College London, Randall Division of Cell & Molecular Biophysics, MRC & Asthma UK Centre in Allergic Mechanisms of Asthma, New Hunt's House, Guy's Hospital Campus London SE1 claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) — with sequence listing part of description (Rule 5.2(a)) 1UL (GB). SUTTON, Brian John; King's College London, Randall Division of Cell & Molecular Biophysics, MRC & Asthma UK Centre in Allergic Mechanisms of Asthma, New Hunt's House, Guy's Hospital Campus London SE1 1UL (GB). WESTWOOD, Marta Katarzyna; c/o IPD, UCB Celltech, 208 Bath Road, Slough Berkshire SL1 3WE (GB). Agent: UCB INTELLECTUAL PROPERTY; c/o UCB (74) = Celltech, 208 Bath Road, Slough Berkshire SL1 3WE (GB). ,_ 1 (54) Title: ANTI-IgE ANTIBODIES (57) : The present invention relates to the area of improved anti-IgE antibodies and antigen binding agents, and compositions GO thereof, which target IgE, for instance: for use in treating disorders caused by IgE (such as allergic responses, or certain autoimmune 6m el responses); and, in particular, disorders caused by the interaction of IgE with the FccRI receptor. In particular, this invention relates ;L to improved anti-IgE antibodies and antigen binding agents related to novel mutants of omalizumab (Xolair®). The improved anti-IgE - antibodies and antigen binding agents of the invention may have improved affinity for IgE and/or an improved interaction with the --.... \" Cz2 domain of IgE and/or an improved modified epitope on IgE (for instance further involving the Cz2 domain of IgE) and/or the Ir- ability to disassociate IgE from the FccRI receptor for instance at pharmaceutically-relevant concentrations. In one aspect, improved Il © or novel treatments for IgE mediated disorders are disclosed in which IgE is targeted (for instance free IgE and/or IgE complexed with N 1 the FccRI receptor). C
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1610198.2A GB201610198D0 (en) | 2016-06-10 | 2016-06-10 | Anti-ige antibodies |
| GBGB1702435.7A GB201702435D0 (en) | 2016-06-10 | 2017-02-15 | Anti-ige antibodies |
| PCT/EP2017/063916 WO2017211928A1 (en) | 2016-06-10 | 2017-06-08 | ANTI-IgE ANTIBODIES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201810199WA true SG11201810199WA (en) | 2018-12-28 |
Family
ID=56894897
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201810199WA SG11201810199WA (en) | 2016-06-10 | 2017-06-08 | ANTI-IgE ANTIBODIES |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US11214627B2 (en) |
| EP (1) | EP3468995A1 (en) |
| JP (2) | JP7164439B2 (en) |
| KR (1) | KR102456813B1 (en) |
| CN (1) | CN109379892B (en) |
| AR (1) | AR108707A1 (en) |
| AU (1) | AU2017277600A1 (en) |
| BR (1) | BR112018074838A2 (en) |
| CA (1) | CA3027120A1 (en) |
| CL (2) | CL2018003556A1 (en) |
| CO (1) | CO2018013006A2 (en) |
| EA (1) | EA201990004A1 (en) |
| EC (1) | ECSP19001438A (en) |
| GB (2) | GB201610198D0 (en) |
| IL (2) | IL263452B2 (en) |
| MA (1) | MA45231A (en) |
| MX (1) | MX2018014761A (en) |
| PE (1) | PE20190212A1 (en) |
| PH (1) | PH12018502574A1 (en) |
| SG (1) | SG11201810199WA (en) |
| TN (1) | TN2018000423A1 (en) |
| TW (1) | TW201802114A (en) |
| UA (1) | UA126468C2 (en) |
| UY (1) | UY37290A (en) |
| WO (1) | WO2017211928A1 (en) |
| ZA (2) | ZA201807822B (en) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018037092A1 (en) * | 2016-08-26 | 2018-03-01 | Sanofi | Multispecific antibodies facilitating selective light chain pairing |
| EP3774925A1 (en) | 2018-04-13 | 2021-02-17 | Institut national de la santé et de la recherche médicale (INSERM) | Fc-engineered anti-human ige antibodies and methods of use |
| AU2019361247A1 (en) * | 2018-10-16 | 2021-05-27 | UCB Biopharma SRL | Method for the treatment of Myasthenia Gravis |
| GB2589049C (en) * | 2019-04-11 | 2024-02-21 | argenx BV | Anti-IgE antibodies |
| WO2021003739A1 (en) * | 2019-07-11 | 2021-01-14 | 武汉友芝友生物制药有限公司 | Tetravalent symmetric bispecific antibody |
| CN113372450A (en) * | 2020-03-10 | 2021-09-10 | 北京万华生物工程有限公司 | IgE chimeric bispecific antibody preparation and application |
| US20230183810A1 (en) * | 2020-05-04 | 2023-06-15 | Dna-Seq, Inc. | Methods and systems for determination of an effective therapeutic regimen and drug discovery |
| WO2021250546A1 (en) | 2020-06-09 | 2021-12-16 | University Of Washington | Micrornas as predictors of response to anti-ige therapies in chronic spontaneous urticaria |
| CN111875706B (en) * | 2020-07-16 | 2021-03-30 | 广州康盛生物科技股份有限公司 | Single-domain antibody of anti-human IgE protein and application thereof |
| WO2022061236A1 (en) * | 2020-09-21 | 2022-03-24 | The Board Of Trustees Of The Leland Stanford Junior University | High affinity anti-ige antibodies |
| US20230122862A1 (en) * | 2021-10-12 | 2023-04-20 | United BioPharma, Inc. | Treatment of ige-mediated diseases |
| WO2023070502A1 (en) * | 2021-10-29 | 2023-05-04 | 天辰生物医药(苏州)有限公司 | Isolated antigen binding protein and use thereof |
| CN114028569B (en) * | 2021-12-20 | 2023-04-28 | 中国医学科学院基础医学研究所 | Use of immunoglobulin IgE for diagnosis and/or treatment of hypertension |
| CN114504644B (en) * | 2021-12-24 | 2024-02-13 | 北京大学第一医院 | Use of anti-IgE antibodies for the treatment of adenoid hypertrophy |
| WO2024003376A1 (en) * | 2022-07-01 | 2024-01-04 | Alk-Abelló A/S | Displacers of ige-fceri |
| CN116143932A (en) * | 2022-12-07 | 2023-05-23 | 南开大学 | Antibody or antigen binding fragment thereof against IgE and Fc variant |
Family Cites Families (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US6492107B1 (en) | 1986-11-20 | 2002-12-10 | Stuart Kauffman | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
| DE3546806C2 (en) | 1985-03-30 | 1991-03-28 | Marc Genf/Geneve Ch Ballivet | |
| DK336987D0 (en) | 1987-07-01 | 1987-07-01 | Novo Industri As | immobilization |
| US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| DE3600905A1 (en) | 1986-01-15 | 1987-07-16 | Ant Nachrichtentech | METHOD FOR DECODING BINARY SIGNALS AND VITERBI DECODERS AND APPLICATIONS |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| GB8719042D0 (en) | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
| GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
| JP2919890B2 (en) | 1988-11-11 | 1999-07-19 | メディカル リサーチ カウンスル | Single domain ligand, receptor consisting of the ligand, method for producing the same, and use of the ligand and the receptor |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8907617D0 (en) | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
| CA2016841C (en) | 1989-05-16 | 1999-09-21 | William D. Huse | A method for producing polymers having a preselected activity |
| AU652539B2 (en) | 1989-05-16 | 1994-09-01 | Medical Research Council | Co-expression of heteromeric receptors |
| CA2016842A1 (en) | 1989-05-16 | 1990-11-16 | Richard A. Lerner | Method for tapping the immunological repertoire |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| WO1992002551A1 (en) | 1990-08-02 | 1992-02-20 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| WO1993004173A1 (en) | 1991-08-14 | 1993-03-04 | Genentech, Inc. | Immunoglobulin variants for specific fc epsilon receptors |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| GB9120467D0 (en) | 1991-09-26 | 1991-11-06 | Celltech Ltd | Anti-hmfg antibodies and process for their production |
| EP1291360A1 (en) | 1991-12-13 | 2003-03-12 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| FR2716640B1 (en) | 1994-02-28 | 1996-05-03 | Procedes Machines Speciales | Device for centering and blocking a workpiece with a view to running it in using an expansion lapper. |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| ZA966075B (en) | 1995-07-27 | 1998-01-19 | Genentech Inc | Protein formulation. |
| JPH11510170A (en) | 1995-07-27 | 1999-09-07 | ジェネンテック インコーポレーテッド | Protein Formula |
| ZA971607B (en) * | 1996-03-12 | 1998-08-25 | Univ Johns Hopkins | Methods of treatment of allergic diseases |
| US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
| US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
| GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| US6172213B1 (en) * | 1997-07-02 | 2001-01-09 | Genentech, Inc. | Anti-IgE antibodies and method of improving polypeptides |
| US5994511A (en) | 1997-07-02 | 1999-11-30 | Genentech, Inc. | Anti-IgE antibodies and methods of improving polypeptides |
| WO1999038531A1 (en) * | 1998-01-29 | 1999-08-05 | Tanox, Inc. | TREATING ATOPIC DERMATITIS WITH IgE ANTAGONISTS |
| GB9812545D0 (en) | 1998-06-10 | 1998-08-05 | Celltech Therapeutics Ltd | Biological products |
| AU5020700A (en) * | 1999-05-26 | 2000-12-18 | Tanox, Inc. | Treating allergic diseases with immunotherapy and ige antagonists |
| CA2380443C (en) | 2000-05-26 | 2013-03-12 | Ginette Dubuc | Single-domain antigen-binding antibody fragments derived from llama antibodies |
| US6908963B2 (en) | 2001-10-09 | 2005-06-21 | Nektar Therapeutics Al, Corporation | Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith |
| GB0129105D0 (en) | 2001-12-05 | 2002-01-23 | Celltech R&D Ltd | Expression control using variable intergenic sequences |
| JP4603894B2 (en) | 2002-12-03 | 2010-12-22 | ユセベ ファルマ ソシエテ アノニム | Assays to identify antibody producing cells |
| GB0312481D0 (en) | 2003-05-30 | 2003-07-09 | Celltech R&D Ltd | Antibodies |
| PL1644412T5 (en) | 2003-07-01 | 2019-01-31 | Ucb Biopharma Sprl | Modified antibody fab fragments |
| GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| WO2005014655A2 (en) | 2003-08-08 | 2005-02-17 | Fresenius Kabi Deutschland Gmbh | Conjugates of hydroxyalkyl starch and a protein |
| GB0411186D0 (en) | 2004-05-19 | 2004-06-23 | Celltech R&D Ltd | Biological products |
| GB0412181D0 (en) | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
| GB0502358D0 (en) | 2005-02-04 | 2005-03-16 | Novartis Ag | Organic compounds |
| EP2500352A1 (en) | 2005-08-19 | 2012-09-19 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| GB0619291D0 (en) | 2006-09-29 | 2006-11-08 | Ucb Sa | Altered antibodies |
| PA8775101A1 (en) * | 2007-04-02 | 2008-11-19 | Pfizer | ANTI-IGE ANTIBODIES |
| CN101801407B (en) * | 2007-06-05 | 2013-12-18 | 耶鲁大学 | Inhibitors of receptor tyrosine kinases and methods of use thereof |
| EP2195341B1 (en) | 2007-09-26 | 2017-03-22 | UCB Biopharma SPRL | Dual specificity antibody fusions |
| JP5571567B2 (en) | 2007-12-21 | 2014-08-13 | メディミューン リミテッド | Binding member for interleukin-4 receptor α (IL-4Rα) -173 |
| JP5470817B2 (en) | 2008-03-10 | 2014-04-16 | 日産自動車株式会社 | Battery electrode, battery using the same, and manufacturing method thereof |
| CN101230103B (en) * | 2008-03-25 | 2011-09-07 | 中国医药集团总公司四川抗菌素工业研究所 | Human recombinant anti-IgE antibody |
| WO2010035012A1 (en) | 2008-09-26 | 2010-04-01 | Ucb Pharma S.A. | Biological products |
| EP2475682B1 (en) | 2009-09-10 | 2018-01-31 | UCB Biopharma SPRL | Multivalent antibodies |
| CN102695956B (en) | 2009-10-26 | 2015-12-09 | 基因泰克公司 | For detecting the determination method of the specific antibody of therapeutic anti-IgE antibodies and the purposes in allergic reaction thereof |
| CN103298834A (en) | 2010-08-03 | 2013-09-11 | Abbvie公司 | Dual variable domain immunoglobulins and uses thereof |
| CA2856216C (en) * | 2011-11-11 | 2021-01-12 | Ucb Pharma S.A. | Albumin binding antibodies and binding fragments thereof |
| AR091305A1 (en) | 2012-01-31 | 2015-01-28 | Genentech Inc | ANTI-IgE ANTIBODIES AND THEIR METHODS OF USE |
| WO2013181577A2 (en) | 2012-06-01 | 2013-12-05 | Momenta Pharmaceuticals, Inc. | Methods related to omalizumab |
| JP6136279B2 (en) | 2013-01-15 | 2017-05-31 | 株式会社ジェイテクト | Rolling bearing device |
| TWI503850B (en) | 2013-03-22 | 2015-10-11 | Polytronics Technology Corp | Over-current protection device |
| WO2015013668A1 (en) * | 2013-07-26 | 2015-01-29 | Ke Zhang | Anti-immunoglobulin e antibodies and methods of use thereof |
| TWI510996B (en) | 2013-10-03 | 2015-12-01 | Acer Inc | Methods for controlling a touch panel and portable computers using the same |
| CN104987412A (en) | 2015-07-14 | 2015-10-21 | 上海拜豪生物科技有限公司 | Arsenic-IgE chelate as well as preparation method and application thereof |
| US20180273626A1 (en) * | 2015-09-11 | 2018-09-27 | The Board Of Trustees Of The Leland Stanford Junio University | Omalizumab resistant ige variants and their use in anti-ige therapy |
| US9816280B1 (en) | 2016-11-02 | 2017-11-14 | Matthew Reitnauer | Portable floor |
-
2016
- 2016-06-10 GB GBGB1610198.2A patent/GB201610198D0/en not_active Ceased
-
2017
- 2017-02-15 GB GBGB1702435.7A patent/GB201702435D0/en not_active Ceased
- 2017-06-08 BR BR112018074838-2A patent/BR112018074838A2/en unknown
- 2017-06-08 UA UAA201812606A patent/UA126468C2/en unknown
- 2017-06-08 PE PE2018003194A patent/PE20190212A1/en unknown
- 2017-06-08 EA EA201990004A patent/EA201990004A1/en unknown
- 2017-06-08 IL IL263452A patent/IL263452B2/en unknown
- 2017-06-08 TN TNP/2018/000423A patent/TN2018000423A1/en unknown
- 2017-06-08 CN CN201780035921.3A patent/CN109379892B/en active Active
- 2017-06-08 MA MA045231A patent/MA45231A/en unknown
- 2017-06-08 JP JP2018564417A patent/JP7164439B2/en active Active
- 2017-06-08 IL IL309516A patent/IL309516A/en unknown
- 2017-06-08 SG SG11201810199WA patent/SG11201810199WA/en unknown
- 2017-06-08 US US16/307,454 patent/US11214627B2/en active Active
- 2017-06-08 CA CA3027120A patent/CA3027120A1/en active Pending
- 2017-06-08 WO PCT/EP2017/063916 patent/WO2017211928A1/en unknown
- 2017-06-08 KR KR1020197000968A patent/KR102456813B1/en active IP Right Grant
- 2017-06-08 MX MX2018014761A patent/MX2018014761A/en unknown
- 2017-06-08 EP EP17731090.1A patent/EP3468995A1/en active Pending
- 2017-06-08 AU AU2017277600A patent/AU2017277600A1/en active Pending
- 2017-06-09 UY UY0001037290A patent/UY37290A/en not_active Application Discontinuation
- 2017-06-09 TW TW106119366A patent/TW201802114A/en unknown
- 2017-06-09 AR ARP170101588A patent/AR108707A1/en unknown
-
2018
- 2018-11-20 ZA ZA2018/07822A patent/ZA201807822B/en unknown
- 2018-11-30 CO CONC2018/0013006A patent/CO2018013006A2/en unknown
- 2018-12-06 PH PH12018502574A patent/PH12018502574A1/en unknown
- 2018-12-10 CL CL2018003556A patent/CL2018003556A1/en unknown
-
2019
- 2019-01-08 EC ECSENADI20191438A patent/ECSP19001438A/en unknown
-
2020
- 2020-02-07 ZA ZA2020/00803A patent/ZA202000803B/en unknown
-
2021
- 2021-10-14 CL CL2021002696A patent/CL2021002696A1/en unknown
- 2021-12-03 US US17/541,932 patent/US20220235146A1/en active Pending
-
2022
- 2022-10-20 JP JP2022168571A patent/JP2023021974A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201810199WA (en) | ANTI-IgE ANTIBODIES | |
| SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
| SG11201907753TA (en) | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201906341XA (en) | Improved serum albumin binders | |
| SG11201906264YA (en) | Improved serum albumin binders | |
| SG11201810149VA (en) | Anti hla-g specific antibodies | |
| SG11201809064QA (en) | Chimeric neurotoxins | |
| SG11201810697QA (en) | Chimeric antigen receptor and car-t cells that bind bcma | |
| SG11201900885VA (en) | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule | |
| SG11201810023QA (en) | Anti-tim-3 antibodies and methods of use thereof | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201909646TA (en) | Trem2 antigen binding proteins and uses thereof | |
| SG11201811184UA (en) | Lag -3 binding members | |
| SG11201809041TA (en) | Compositions and methods for selective protein expression | |
| SG11201807437XA (en) | Antibodies specific to human poliovirus receptor (pvr) | |
| SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
| SG11201909022PA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
| SG11201805420SA (en) | Antibodies and conjugates thereof | |
| SG11201907583TA (en) | Methods for treating complement-mediated diseases and disorders | |
| SG11202000105QA (en) | Anti-cd166 antibodies and uses thereof | |
| SG11201906319XA (en) | Compositions and methods for the depletion of cd137+ cells | |
| SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
| SG11201408780XA (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| SG11201903154YA (en) | Antibodies that bind zika virus envelope protein and uses thereof |